HBV
Chronic HBV infection can lead to advanced liver disease, including cirrhosis and hepatocellular carcinoma. Hepatitis B is viewed as a specific immunity-mediated liver disease. Control of covalently closed circular DNA (cccDNA) amplification is an important feature necessary for the ability of hepadnaviruses to persistently infect cells, without cytopathic effects. The high level of viral replication and cccDNA copy number induce cytopathic changes in both cell culture and the livers of infected animals. HBV replication may also disturb intracellular organelles, causing ER stress and alteration of mitochondrial function and increased replication may lead to depletion of cellular molecular resources like phospholipids that are needed for synthesis of cellular membrane, lipoproteins, and HBV sub and full viral particles. Liver injury can be caused not only by high levels of viral replication in infected hepatocytes, but also by the accumulation of the viral proteins in the absence of HBV replication in hepatocytes. Accumulation of viral proteins does occur in livers of patients with chronic HBV infection.
References
1.Zhang YY and Hu KQ. J Med Virol. 2015;87(12):1989–1999.
References
1.Zhang YY and Hu KQ. J Med Virol. 2015;87(12):1989–1999.
Microbiology/Virology
HBV
-
HBV-IN-37
catalog no : M37076
cas no: 380483-01-2
HBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and can be used for hepatitis B disease-related research. -
Burfiralimab
catalog no : M36776
cas no: 2460809-80-5
Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research. -
ccc_R08
catalog no : M36524
cas no: 2919019-72-8
ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV). -
Antiviral agent
catalog no : M36065
cas no: 380458-45-7
Antiviral agent is thiazolidin-4-one with anti-hepatitis B activity -
Linvencorvir
catalog no : M35768
cas no: 1808248-05-6
Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.